We attribute this to the high toxicity of the FoxO1 inhibitor alone (cell killing ~70%), and it demonstrates that CLL cells exposed to ibrutinib are sensitive to FoxO1 inhibition. The gene discussed is FOXO1; the disease is B-cell chronic lymphocytic leukemia.